Recruiting NCT06262594

Lemborexant Treatment of Insomnia Linked to Epilepsy

Phase III Interventional Epilepsy Sleep

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied: The protocol lists: Lemborexant, Placebo.
Who it may be relevant to: Registry conditions: Epilepsy, Sleep. Basic parameters: from 18 years · All.
What needs checking: Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place: United States, Canada
Next step: Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

The goal of this clinical trial is to assess whether Lemborexant can improve sleep in patients with epilepsy.

Changes in antiseizure medication 1 month before study protocol or during study protocol
Concomitant medications per SUNRISE1
Individuals with hepatic impairment
Female participants who are pregnant or breastfeeding
Individuals with compromised respiratory function
Individuals with a history of complex sleep-related behaviour
Individuals with rare hereditary diseases of galactose intolerance such as galactosemia or glucose-galactose malabsorption
Individuals with a history of dependence or tolerance - abuse, dependence, rebound insomnia
Individuals with psychiatric disorders with abnormal thinking and behavioural changes, depression, or suicidal ideation
Individuals with a diagnosis of narcolepsy

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

United States · 1 center

Canada · 1 center

NCT: NCT06262594 · L'ÉTOILE